Meves Pharmaceuticals
New York
About Meves Pharmaceuticals
Meves Pharmaceuticals is developing nucleoside based therapies for mitochondrial DNA (mtDNA) depletion syndromes (MDS or MDDS), a category of severe genetic diseases. The initial focus is on therapy tailored specifically to treat patients with Thymidine Kinase 2 (TK2) deficiency, a discrete monogenic disorder associated with profound skeletal myopathy.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $10.9M
- Last round: Series Unknown (Mar 2018)
- Website: mevespharma.com
- Phone: +1 510-375-1669
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Canonical: https://fsome.com/organization/meves-pharmaceuticals-196384 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.